| Entry |
|
|---|
| Name |
Ixazomib (USAN) |
|---|
| Formula |
C14H19BCl2N2O4
|
|---|
| Exact mass |
360.0815
|
|---|
| Mol weight |
361.03
|
|---|
| Structure |
|
|---|
| Class |
Antineoplastic
DG03134 Proteasome inhibitor
|
|---|
| Remark |
| Product (DG01269): | D10131<JP/US> |
|
|---|
| Efficacy |
Antineoplastic, Proteasome inhibitor |
|---|
| Comment |
Peptide boronic acid analog
Ixazomib inhibits the chymotrypsin-like subunit (beta 5) of the 20S proteasome reversibly.
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XG Proteasome inhibitors
L01XG03 Ixazomib
D10130 Ixazomib (USAN)
Drug groups [BR:br08330]
Antineoplastic
DG03134 Proteasome inhibitor
DG01269 Ixazomib
D10130 Ixazomib
Target-based classification of drugs [BR:br08310]
Peptidases and inhibitors
Threonine peptidases
Proteasome family
PSMB5
D10130 Ixazomib (USAN)
Drug groups [BR:br08330]
Antineoplastic
DG03134 Proteasome inhibitor
DG01269 Ixazomib
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 23
1 C5a C 12.1800 -17.2200
2 N1b N 13.3924 -17.9200
3 C8y C 10.9676 -17.9200
4 O5a O 12.1800 -15.8200
5 C1b C 14.5879 -17.2296
6 C5a C 15.7753 -17.9151
7 N1b N 16.9665 -17.2271
8 O5a O 15.7755 -19.3198
9 C1c C 18.1560 -17.9138
10 C1b C 19.3461 -17.2265
11 Z B 18.1562 -19.3198
12 C1c C 20.5362 -17.9135
13 C1a C 21.7260 -17.2263
14 C1a C 20.5364 -19.3198
15 C8x C 9.7721 -17.2296
16 C8y C 8.5596 -17.9295
17 C8x C 8.5594 -19.3295
18 C8x C 9.7549 -20.0199
19 C8y C 10.9674 -19.3200
20 X Cl 12.1966 -20.0300
21 X Cl 7.3284 -17.2185
22 O1a O 19.3491 -20.0084
23 O1a O 16.9242 -20.0314
BOND 23
1 1 2 1
2 1 3 1
3 1 4 2
4 2 5 1
5 5 6 1
6 6 7 1
7 6 8 2
8 7 9 1
9 9 10 1
10 9 11 1 #Up
11 10 12 1
12 12 13 1
13 12 14 1
14 3 15 2
15 15 16 1
16 16 17 2
17 17 18 1
18 18 19 2
19 3 19 1
20 19 20 1
21 16 21 1
22 11 22 1
23 11 23 1
|
|---|
